 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Enlivex Therapeutics price target lowered to $12 from $15 at H.C. Wainwright

Enlivex Therapeutics to reduce workforce by 50%

Enlivex Therapeutics announces reprioritization plan

The Company intends to increase its existing focus on inflammatory and autoimmune indications. The Company, since its inception, considered the inherent properties of AllocetraTM as an innovative...

Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results

Nes-Ziona, Israel, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company...

Enlivex to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Data published in Frontiers in Immunology show a robust safety profile and rapid resolution from ARDS and parallel resolution of inflammation markers and elevated cytokines/chemokines, as well as substantial improvements in mortality in 21 Allocetra-treated patients with COVID-19 vs. matched ...

Enlivex Announces Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data Details Resolution of Acute Respiratory Distress Syndrome (ARDS) from two Phase I/II Trials Evaluating Allocetra in Patients with COVID-19

Nes-Ziona, Israel, July 31, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the Company), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the first patient has been dosed under the amended protocol for the Companys Phase II trial evaluating ...

Nes-Ziona, Israel, July 31, 2023...

Enrollment of patients in the Phase I/II evaluating Allocetra in combination with chemotherapy in patients with peritoneal metastases from advanced solid tumors is proceeding as planned, with 50% (lower dose cohorts) already enrolled.The integration of tislelizumab, an anti-PD-1 immune checkpoint ...

Enlivex Announces First Quarter 2023 Financial Results and Provides a Business Update

Enlivex Therapeutics Ltd. (NASDAQ:ENLV Get Rating) was the target of a significant decline in short interest during the month of May. As of May 31st, there was short interest totalling 121,200 shares, a decline of 5.8% from the May 15th total of 128,700 shares. Based on an average daily trading ...

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Down 5.8% in May

Enlivex Therapeutics Ltd. (NASDAQ:ENLV  Get Rating) was the target of a significant decline in short interest during the month of May. As of May 31st, there was short interest totalling 121,200 shares, a decline of 5.8% from the May 15th total of 128,700 shares. Based on an average daily ...

Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded by Dror Mevorach on January 22, 2012 and is headquartered in Ness Ziona, Israel.

Watchers	6,333
52-Wk Low	$1.45
52-Wk High	$4.92

Market Cap	$27.14M
Volume (M)	2,858.00
52-Wk High	$4.92
52-Wk Low	$1.45

ENLV Enlivex Therapeutics Ltd

About

Feed

News

Sentiment

Fundamentals